89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the 51% of ...
THIO combined with Libtayo shows a 38% ORR in advanced NSCLC resistant to checkpoint inhibitors, surpassing standard therapies. The phase 2 THIO-101 trial reports a disease control rate of 85% in ...
Libtayo showed similar SPT rates to placebo but improved DFS in high-risk CSCC patients post-surgery and radiotherapy. The C-POST trial demonstrated Libtayo's superior DFS rates, with 81.1% at 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results